## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 30.7% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($62.06)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. B of A Securities Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation**
- Source: Nasdaq | 20251210T000925 | Somewhat-Bullish | Relevance: 98%
- B of A Securities has reiterated its Buy recommendation for Arrowhead Pharmaceuticals (ARWR). Despite an average one-year price target suggesting a 13.65% downside from its current share price, institutional ownership in ARWR has increased, indicating a bullish outlook. Key institutional holders include Avoro Capital Advisors and iShares Core S&P Small-Cap ETF.

**2. Arrowhead Pharmaceuticals stock hits 52-week high at 71.62 USD**
- Source: Investing.com | 20251211T150851 | Bullish | Relevance: 97%
-  Arrowhead Pharmaceuticals (ARWR) stock has reached a new 52-week high of $71.62 USD, reflecting a significant 221.09% surge over the past year and strong investor confidence. Despite this, InvestingPro analysis suggests the stock is trading above its Fair Value and is in overbought territory. The company has also made progress in drug development, receiving FDA Breakthrough Therapy designation for plozasiran and initiating a Phase 1/2a clinical trial for ARO-MAPT, leading analysts to adjust their price targets upwards.

**3. Arrowhead Pharmaceuticals (ARWR) Is Up 22.0% After FDA Grants Breakthrough Status to Plozasiran**
- Source: Simply Wall Street | 20251209T020931 | Bullish | Relevance: 97%
-  Arrowhead Pharmaceuticals recently received FDA Breakthrough Therapy designation for its investigational RNAi drug plozasiran, aimed at severe hypertriglyceridemia. This boosts the company's cardiometabolic RNAi platform, with plans to complete Phase 3 trials and submit an sNDA by late 2026. The approval highlights the company's reliance on partner payments while also emphasizing the critical role of regulatory outcomes for its future investment narrative.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.3%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +39%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.0% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -30% YoY, concerning. Analyst sentiment positive (9 raises, avg +39%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from 26.8% to 30.7% (+4.0% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (30.7% > 10.0%), caution on chasing. MRS_5 at 4.6% confirms short-term momentum alignment. AM_20 at 33.1% shows strong absolute momentum above own 20MA. Outperforming sector by 33.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.70), confirming momentum. RSI overbought at 78, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 30.74% (CS: 99) | Strong |
| RSI_14 | 77.5 | Overbought |
| MACD Histogram | 1.70 | Bullish |
| vs SMA20 | 1.331x | Above |
| vs SMA50 | 1.597x | Above |
| vs SMA200 | 2.885x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $70.82
- **Stop Loss:** $62.06 (12.4% risk)
- **Target:** $79.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 157
- **Position Value:** $11,118.74
- **Portfolio %:** 11.12%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*